Calithera Biosciences

BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace
layoffs
Grifols
Frequency Therapeutics
Eliem Therapeutics
Aligos Therapeutics
Thermo Fisher Scientific
Magenta Therapeutics
Eisai
Amgen
Y-mAbs Therapeutics
Century Therapeutics
Elevation Oncology
Calithera Biosciences
Editas Medicine
Verily
Abzena
Flag link:
Calithera buys itself a plan B
Calithera buys itself a plan B
EP Vantage
Calithera Biosciences
Takeda
telaglenastat
sapanisertib
mivovatinib
lung cancer
B cell lymphoma
Flag link:
Calithera flunks phase 2 cancer trial, axes 35% of staff
Calithera flunks phase 2 cancer trial, axes 35% of staff
Fierce Biotech
Calithera Biosciences
clinical trials
telaglenastat
renal cell carcinoma
layoffs
Flag link:
The Week Ahead In Biotech: Spotlight On ESMO Conference
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Motif Biosciences
Iclaprim
Merck
Keytruda
melanoma
JNJ
esketamine
ASCO
Pfizer
Veru. earnings
Aveo Pharmaceuticals
Calithera Biosciences
Flag link:
FDA Fast Tracks Calithera Biosciences' CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma
FDA Fast Tracks Calithera Biosciences' CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma
CP Wire
Calithera Biosciences
CB-839
cabozantinib
metastatic renal cell carcinoma
Flag link:
3 Strong Biotech Stocks In 2017
3 Strong Biotech Stocks In 2017
Forbes
Regeneron
Calithera Biosciences
Dynavax Technologies
Flag link: